Patents by Inventor Yuqiao Shen

Yuqiao Shen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) for use in treatment of diseases associated with a PTEN deficiency
    Patent number: 10493078
    Abstract: A compound having the structure set forth in Formula (I) and Formula (II): wherein the substituents Y, Z, A, B, R1, R2, R3, R4 and R5 are as defined herein. Provided herein are inhibitors of poly(ADP-ribose)polymerase activity. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat diseases, disorders and conditions associated with a PTEN deficiency that are ameliorated by the inhibition of PARP activity.
    Type: Grant
    Filed: August 3, 2018
    Date of Patent: December 3, 2019
    Assignee: Medivation Technologies LLC
    Inventors: Daniel Chu, Bing Wang, Ying Feng, Yuqiao Shen, Leonard E. Post
  • DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) FOR USE IN TREATMENT OF DISEASES ASSOCIATED WITH A PTEN DEFICIENCY
    Publication number: 20190070189
    Abstract: A compound having the structure set forth in Formula (I) and Formula (II): wherein the substituents Y, Z, A, B, R1, R2, R3, R4 and R5 are as defined herein. Provided herein are inhibitors of poly(ADP-ribose)polymerase activity. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat diseases, disorders and conditions associated with a PTEN deficiency that are ameliorated by the inhibition of PARP activity.
    Type: Application
    Filed: August 3, 2018
    Publication date: March 7, 2019
    Inventors: Daniel CHU, Bing WANG, Ying FENG, Yuqiao SHEN, Leonard E. POST
  • TREATMENT OF SMALL CELL LUNG CANCER WITH A PARP INHIBITOR
    Publication number: 20190054087
    Abstract: Described are methods of treatment of a small cell lung cancer subject expressing Schlafen-11 (SLFN 11) with a Poly (ADP-ribose) polymerases (PARP) inhibitor or a pharmaceutically acceptable salt thereof. Specifically, the method comprising detecting SLFN 11 in a tumor cell sample from the subject, and administering effective amount of a PARP inhibitor, such as talazoparib or the tosylate salt of talazoparib, to the subject.
    Type: Application
    Filed: October 26, 2016
    Publication date: February 21, 2019
    Applicant: Medivation Technologies LLC
    Inventors: Ying FENG, Leonard E. POST, Yuqiao SHEN, Yuanbin RU, Evelyn WANG, Karen YU
  • DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) FOR USE IN TREATMENT OF DISEASES ASSOCIATED WITH A PTEN DEFICIENCY
    Publication number: 20150209363
    Abstract: A compound having the structure set forth in Formula (I) and Formula (II): wherein the substituents Y, Z, A, B, R1, R2, R3, R4 and R5 are as defined herein. Provided herein are inhibitors of poly(ADP-ribose)polymerase activity. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat diseases, disorders and conditions associated with a PTEN deficiency that are ameliorated by the inhibition of PARP activity.
    Type: Application
    Filed: March 27, 2015
    Publication date: July 30, 2015
    Inventors: Daniel Chu, Bing Wang, Ying Feng, Yuqiao Shen, Leonard Edwin Post
  • Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) for use in treatment of diseases associated with a PTEN deficiency
    Patent number: 9018201
    Abstract: A compound having the structure set forth in Formula (I) and Formula (II): wherein the substituents Y, Z, A, B, R1, R2, R3, R4 and R5 are as defined herein. Provided herein are inhibitors of poly(ADP-ribose)polymerase activity. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat diseases, disorders and conditions associated with a PTEN deficiency that are ameliorated by the inhibition of PARP activity.
    Type: Grant
    Filed: August 21, 2013
    Date of Patent: April 28, 2015
    Assignee: Biomarin Pharmaceuticial Inc.
    Inventors: Daniel Chu, Bing Wang, Ying Feng, Yuqiao Shen, Leonard Edwin Post
  • DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) FOR USE IN TREATMENT OF DISEASES ASSOCIATED WITH A PTEN DEFICIENCY
    Publication number: 20140066429
    Abstract: A compound having the structure set forth in Formula (I) and Formula (II): wherein the substituents Y, Z, A, B, R1, R2, R3, R4 and R5 are as defined herein. Provided herein are inhibitors of poly(ADP-ribose)polymerase activity. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat diseases, disorders and conditions associated with a PTEN deficiency that are ameliorated by the inhibition of PARP activity.
    Type: Application
    Filed: August 21, 2013
    Publication date: March 6, 2014
    Applicant: BIOMARIN PHARMACEUTICAL INC.
    Inventors: Daniel Chu, Bing Wang, Ying Feng, Yuqiao Shen, Leonard Edwin Post
  • Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) for use in treatment of diseases associated with a PTEN deficiency
    Patent number: 8541403
    Abstract: A compound having the structure set forth in Formula (I) and Formula (II): wherein the substituents Y, Z, A, B, R1, R2, R3, R4 and R5 are as defined herein. Provided herein are inhibitors of poly(ADP-ribose)polymerase activity. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat diseases, disorders and conditions associated with a PTEN deficiency that are ameliorated by the inhibition of PARP activity.
    Type: Grant
    Filed: February 3, 2011
    Date of Patent: September 24, 2013
    Assignee: BioMarin Pharmaceutical Inc.
    Inventors: Daniel Chu, Bing Wang, Ying Feng, Yuqiao Shen, Leonard Edwin Post
  • DIHYDROPYRIDOPHTHALAZINONE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) FOR USE IN TREATMENT OF DISEASES ASSOCIATED WITH A PTEN DEFICIENCY
    Publication number: 20110190288
    Abstract: A compound having the structure set forth in Formula (I) and Formula (II): wherein the substituents Y, Z, A, B, R1, R2, R3, R4 and R5 are as defined herein. Provided herein are inhibitors of poly(ADP-ribose)polymerase activity. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat diseases, disorders and conditions associated with a PTEN deficiency that are ameliorated by the inhibition of PARP activity.
    Type: Application
    Filed: February 3, 2011
    Publication date: August 4, 2011
    Inventors: Daniel Chu, Bing Wang, Ying Feng, Yuqiao Shen, Leonard Edwin Post
  • Adenovirus E1B-55K single amino acid mutants and methods of use
    Patent number: 7785887
    Abstract: Adenoviral mutants are described that have single amino acid mutations in the E1B-55K protein which mutations effect the p53 binding/inactivation and the late functions of the E1B-55K protein in a manner that enhances the efficacy of such viruses for treating cancer when compared to adenoviral mutants that have the E1B-55K region deleted.
    Type: Grant
    Filed: September 24, 2003
    Date of Patent: August 31, 2010
    Assignee: Onyx Pharmaceuticals, Inc.
    Inventors: Yuqiao Shen, Julie Nye, Terry Hermiston
  • Nucleic acids encoding cytosine deaminase
    Patent number: 7556955
    Abstract: A new cytosine deaminase gene and protein from Candida kefyr are provided. This protein has increased ability to convert the 5-fluorocytosine prodrug to its toxic form when compared against the E. coli enzyme.
    Type: Grant
    Filed: July 20, 2006
    Date of Patent: July 7, 2009
    Assignee: Onyx Pharmaceuticals, Inc.
    Inventors: Yuqiao Shen, Sylvie Laquerre, Amy M. Delaney, Charles A. Omer
  • Antibody that specifically binds to Cytosine deaminase
    Patent number: 7414113
    Abstract: A new cytosine deaminase gene and protein from Candida kefyr are provided. This protein has increased ability to convert the 5-fluorocytosine prodrug to its toxic form when compared against the E. coli enzyme.
    Type: Grant
    Filed: July 20, 2006
    Date of Patent: August 19, 2008
    Assignee: Onyx Pharmaceuticals, Inc.
    Inventors: Yuqiao Shen, Sylvie Laquerre, Amy M. Delaney, Charles A. Omer
  • Oncolytic adenovirus
    Patent number: 7396679
    Abstract: Viral vectors and methods of making such vectors are described that preferentially kill neoplastic but not normal cells, the preferred vector being an adenovirus that has the endogenous promoters in the E1A and/or E4 regions substituted with a tumor specific promoter which is preferably E2F responsive.
    Type: Grant
    Filed: November 25, 2002
    Date of Patent: July 8, 2008
    Assignee: Onyx Pharmaceuticals, Inc.
    Inventors: Leisa Johnson, Ali Fattaey, Terry Hermiston, Yuqiao Shen, Sylvie Laquerre
  • Anti-Tumor Activity of an Oncolytic Adenovirus-Delivered Oncogene siRNA
    Publication number: 20070258952
    Abstract: The present invention includes compositions and methods for the knockdown of one or more genes to a target cell in need of gene therapy by using an siRNA transgene that is integrated into a replication-competent, oncolytic adenovirus.
    Type: Application
    Filed: May 4, 2007
    Publication date: November 8, 2007
    Applicants: BAYLOR RESEARCH INSTITUTE, MUREX PHARMACEUTICALS, BAYLOR UNIVERSITY
    Inventors: Alex W. Tong, Yu An Zhang, John J. Nemunaitis, Yuqiao Shen, Po-hsun Chen, Shirley K. Samuel
  • Candida Kefyr Cytosine Deaminase
    Publication number: 20070026491
    Abstract: A new cytosine deaminase gene and protein from Candida kefyr are provided. This protein has increased ability to convert the 5-fluorocytosine prodrug to its toxic form when compared against the E. coli enzyme.
    Type: Application
    Filed: July 20, 2006
    Publication date: February 1, 2007
    Applicant: Onyx Pharmaceuticals, Inc.
    Inventors: Yuqiao Shen, Sylvie Laquerre, Charles Omer, Amy Delaney
  • Candida Kefyr Cytosine Deaminase
    Publication number: 20060286592
    Abstract: A new cytosine deaminase gene and protein from Candida kefyr are provided. This protein has increased ability to convert the 5-fluorocytosine prodrug to its toxic form when compared against the E. coli enzyme.
    Type: Application
    Filed: July 20, 2006
    Publication date: December 21, 2006
    Applicant: Onyx Pharmaceuticals, Inc.
    Inventors: Yuqiao Shen, Sylvie Laquerre, Charles Omer, Amy Delaney
  • cytosine deaminase
    Patent number: 7141404
    Abstract: A new cytosine deaminase gene and protein from Candida kefyr are provided. This protein has increased ability to convert the 5-fluorocytosine prodrug to its toxic form when compared against the E. coli enzyme.
    Type: Grant
    Filed: December 22, 2003
    Date of Patent: November 28, 2006
    Assignee: Onyx Pharmaceuticals, Inc.
    Inventors: Yuqiao Shen, Sylvie Laquerre, Amy M. Delaney, Charles A. Omer
  • Oncolytic adenovirus
    Patent number: 7078030
    Abstract: Viral vectors and methods of making such vectors are described that preferentially kill neoplastic but not normal cells, the preferred vector being an adenovirus that has the endogenous promoters in the E1A and/or E4 regions substituted with a tumor specific promoter which is preferably E2F responsive.
    Type: Grant
    Filed: December 11, 2003
    Date of Patent: July 18, 2006
    Assignee: Onyx Pharmaceuticals, Inc
    Inventors: Leisa Johnson, Ali Fattaey, Terry Hermiston, Jerry Yuqiao Shen, Sylvie Laquerre
  • Adenovirus E1B-55K single amino acid mutants and methods of use
    Publication number: 20050053581
    Abstract: Adenoviral mutants are described that have single amino acid mutations in the E1B-55K protein which mutations effect the p53 binding/inactivation and the late functions of the E1B-55K protein in a manner that enhances the efficacy of such viruses for treating cancer when compared to adenoviral mutants that have the E1B-55K region deleted.
    Type: Application
    Filed: September 24, 2003
    Publication date: March 10, 2005
    Inventors: Yuqiao Shen, Julie Nye, Terry Hermiston
  • Oncolytic adenovirus
    Publication number: 20040241142
    Abstract: Viral vectors and methods of making such vectors are described that preferentially kill neoplastic but not normal cells, the preferred vector being an adenovirus that has the endogenous promoters in the E1A and/or E4 regions substituted with a tumor specific promoter which is preferably E2F responsive.
    Type: Application
    Filed: December 11, 2003
    Publication date: December 2, 2004
    Inventors: Leisa Johnson, Ali Fattaey, Terry Hermiston, Jerry Yuqiao Shen, Sylvie Laquerre
  • Candida kefyr cytosine deaminase
    Publication number: 20040180418
    Abstract: A new cytosine deaminase gene and protein from Candida kefyr are provided. This protein has increased ability to convert the 5-fluorocytosine prodrug to its toxic form when compared against the E. coli enzyme.
    Type: Application
    Filed: December 22, 2003
    Publication date: September 16, 2004
    Applicant: Onyx Pharmaceuticals, Inc.
    Inventors: Yuqiao Shen, Sylvie Laquerre, Charles A. Omer, Amy M. Delaney